RayKnowChina Research Map
Shortlist0

WuhanHuazhong Univ. of Sci. & Tech. – Tongji Medical College

Union Hospital

华中科技大学同济医学院附属协和医院

Listed for 34 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Union Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌11 papers led1 open trial led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌8 papers led1 open trial led
  3. Hepatocellular carcinoma肝细胞癌144 papers led6 open trials led
  4. Stomach cancer胃癌78 papers led9 open trials led
  5. Hepatoblastoma肝母细胞瘤1 paper led
  6. Retinoblastoma视网膜母细胞瘤2 papers led
  7. Chordoma脊索瘤1 paper led
  8. Osteosarcoma骨肉瘤25 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤18 papers led
  10. Neuroblastoma神经母细胞瘤8 papers led
  11. Ewing sarcoma尤文肉瘤2 papers led
  12. Multiple myeloma多发性骨髓瘤30 papers led5 open trials led
  13. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病3 papers led2 open trials led
  14. Aplastic anaemia再生障碍性贫血2 papers led1 open trial led
  15. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症8 papers led
  16. Haemophilia A血友病 A1 paper led
  17. Fanconi anaemia范可尼贫血1 paper led
  18. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病1 paper led
  19. IgG4-related diseaseIgG4相关性疾病0 papers led
  20. Myasthenia gravis重症肌无力0 papers led1 open trial led
  21. Moyamoya disease烟雾病2 papers led
  22. Biliary atresia胆道闭锁7 papers led
  23. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎2 papers led
  24. Takayasu arteritis大动脉炎1 paper led
  25. Idiopathic pulmonary fibrosis特发性肺纤维化3 papers led
  26. Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
  27. Behçet disease白塞病0 papers led
  28. IgA nephropathyIgA 肾病2 papers led1 open trial led
  29. Osteogenesis imperfecta成骨不全症1 paper led
  30. Primary biliary cholangitis原发性胆汁性胆管炎3 papers led
  31. Primary sclerosing cholangitis原发性硬化性胆管炎0 papers led
  32. Congenital diaphragmatic hernia先天性膈疝1 paper led
  33. Hirschsprung disease先天性巨结肠8 papers led
  34. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Wilson disease, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 11 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
11
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 3320212022: 5520222023: 2220232024: 1120242025: 002025

6 hospitals in Wuhan for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 8

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT07177443

    Age 18 years to 65 years (registered criteria)

    Led by Union HospitalWuhan

  2. Recruiting
    Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07528183

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuhan

  3. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  4. Recruiting
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06839066

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan

  5. Recruiting
    A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT05956587

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChongqing, Fuzhou, Guangzhou, Hangzhou, Linyi, Liuzhou, Nanchang, Tianjin, Wuhan, Xi'an, Zhengzhou

  6. Recruiting
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06239727

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang

  7. Recruiting
    TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06301165

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesDongguan, Foshan, Guangzhou, Shenzhen, Wuhan

  8. Recruiting
    A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
    Phase
    Phase 1
    Started
    2021-11
    Registry
    NCT05194982

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesChangsha, Chongqing, Guangzhou, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueInduction / concurrent chemotherapyRecurrent / metastatic disease
Departments in papersPathology / laboratory medicineENT / head & neck surgeryMedical oncologyRadiology / nuclear medicine
Papers it led11
  1. Deubiquitinase USP7 stabilizes KDM5B and promotes tumor progression and cisplatin resistance in nasopharyngeal carcinoma through the ZBTB16/TOP2A axis.2024Cell death and differentiation
  2. Nomograms incorporating primary tumor response at mid-radiotherapy to predict survival in locoregionally advanced nasopharyngeal carcinoma.2023Head & neck
  3. Down-regulated lncRNA ROR in tumor-educated platelets as a liquid-biopsy biomarker for nasopharyngeal carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  4. Tumor factors associated with in-field failure for nasopharyngeal carcinoma after intensity-modulated radiotherapy.2022Head & neck
  5. Prognostic and clinicopathological significance of lymphocyte-to-monocyte ratio in patients with nasopharyngeal carcinoma.2022Head & neck
  6. Molecular characteristics of pediatric nasopharyngeal carcinoma using whole-exome sequencing.2022Oral oncology
  7. Adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Finding the suitable population.2022Oral oncology
  8. A Bayesian network meta-analysis of the primary definitive therapies for locoregionally advanced nasopharyngeal carcinoma: IC+CCRT, CCRT+AC, and CCRT alone.2022PloS oneFree full text
  9. Prognostic value of pretreatment prognostic nutritional index and lactated dehydrogenase in locally advanced nasopharyngeal carcinoma patients.2021Annals of palliative medicine
  10. Long-term Therapeutic Outcome and Prognostic Factors of Patients with Nasopharyngeal Carcinoma Receiving Intensity-modulated Radiotherapy: An Analysis of 608 Patients from Low-endemic Regions of China.2021Current medical science
  11. A head-to-head comparison of 68Ga-DOTA-FAPI-04 and 18F-FDG PET/MR in patients with nasopharyngeal carcinoma: a prospective study.2021European journal of nuclear medicine and molecular imaging
All its trials on ClinicalTrials.gov, any status24
  1. Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal CarcinomaRecruitingNCT07177443Lead sponsorPhase 3Start 2025-09
  2. Pembrolizumab + MRGOO3 as Neoadjuvant in NPCActive, not recruitingNCT07267338Lead sponsorPhase 2Start 2026-02
  3. The Clinical Application Value of CAIX-Targeted PET Hypoxia Imaging in Malignant TumorsActive, not recruitingNCT07890038Lead sponsorStart 2026-06
  4. Cadonilimab (AK104) in the Treatment of Nasopharyngeal CarcinomaStatus unknownNCT05790200Lead sponsorPhase 2Start 2023-04
  5. Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal CarcinomaRecruitingNCT07528183Study sitePhase 2Start 2026-07
  6. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  7. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingNCT06839066Study sitePhase 2Start 2025-04
  8. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  9. A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Study sitePhase 2Start 2024-01
  10. TPC Versus GP Induction Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06301165Study sitePhase 2Start 2024-03
  11. A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid TumorRecruitingNCT05194982Study sitePhase 1Start 2021-11
  12. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Study sitePhase 2Start 2023-04
  13. Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)Active, not recruitingNCT05587374Study sitePhase 3Start 2023-08
  14. Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal CarcinomaActive, not recruitingNCT05979961Study sitePhase 3Start 2023-09
  15. TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal CarcinomaCompletedNCT05563480Study sitePhase 2Start 2022-10
  16. PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaActive, not recruitingNCT04907370Study sitePhase 3Start 2021-08
  17. Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal CarcinomaCompletedNCT03984357Study sitePhase 2Start 2020-03
  18. Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04215978Study sitePhase 1Start 2020-01
  19. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Study sitePhase 3Start 2019-03
  20. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT03427827Study sitePhase 3Start 2018-07
  21. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Study sitePhase 3Start 2018-10
  22. Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03700476Study sitePhase 3Start 2018-12
  23. Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal CarcinomaStatus unknownNCT02633176Study sitePhase 3Start 2015-01
  24. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal CancerStatus unknownNCT01074021Study sitePhase 3Start 2009-10
More papers found outside PubMed (not counted)34
  1. 1371P Nivolumab plus chemoradiotherapy sparing concurrent cisplatin in nasopharyngeal carcinoma (NPC): Social reintegration and patient-reported outcomes (PROs) in quality-of-life (QoL) and tolerability from a phase II PLATINUM trial2025Annals of Oncologyarticle
  2. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncologyarticle
  3. Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.2025Journal of Clinical Oncologyarticle
  4. Combination of Tim-3 blockade TQB2618 with penpulimab and chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): A multicenter, single-arm, two-cohort, phase 2 study.2025Journal of Clinical Oncologyconference-abstract
  5. DoseNet: Dose-adaptive prediction of the parotid glands deformation for radiotherapy planning2025Image and Vision Computingarticle
  6. Expert-Constrained Deep Learning Framework for Nasopharyngeal Carcinoma Automated Target Delineation2025International Journal of Radiation Oncology*Biology*Physicsarticle
  7. PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized2025Journal of Clinical Oncologyarticle
  8. Unsupervised deep learning model for fast energy layer pre-selection of delivery-efficient proton arc therapy plan optimization of nasopharyngeal carcinoma2025arXiv (Cornell University)preprint
  9. 416P A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with chemotherapy for the treatment of anti-PD-1 resistant, recurrent, or metastatic nasopharyngeal carcinoma (R/M NPC)2024Annals of Oncologyarticle
  10. Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.2024Journal of Clinical Oncologyconference-abstract
  11. Analysis of proliferating Treg cells as a predictor for immunotherapy response using systemic longitudinal immune profiling: Biomarker analysis of the phase 3 CONTINUUM trial.2024Journal of Clinical Oncologyconference-abstract
  12. Anatomical and Dosimetric Variations during VMAT in Patients with Locally Advanced Nasopharyngeal Carcinoma after Induction Therapy: Implications for Adaptive Radiation Therapy2024International Journal of Radiation Oncology*Biology*Physicsarticle
  13. Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.2024Journal of Clinical Oncologyconference-abstract
  14. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncologyconference-abstract
  15. Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter, randomized, phase 2 trial.2024Journal of Clinical Oncologyconference-abstract
  16. Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy.2024Journal of Clinical Oncologyconference-abstract
  17. Nivolumab combined with chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): A multicenter, single-arm, phase II clinical trial.2024Journal of Clinical Oncologyconference-abstract
  18. Nivolumab combined with radical chemoradiotherapy sparing concurrent cisplatin in high-risk locoregionally advanced nasopharyngeal carcinoma (PLATINUM): An investigator-initiated, open-label, multicenter, single-arm, phase II clinical trial2024Journal of Clinical Oncologyconference-abstract
  19. PD-1 blockade with camrelizumab after chemoradiotherapy in nasopharyngeal carcinoma.2024Journal of Clinical Oncologyconference-abstract
  20. Radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy in patients with low-risk nasopharyngeal carcinoma: Updated results from a multicenter, open-label, non-inferiority, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  21. A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors.2023Journal of Clinical Oncologyconference-abstract
  22. A phase Ib/II study of GFH018 in combination with toripalimab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC).2023Journal of Clinical Oncologyconference-abstract
  23. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma2023Holistic Integrative Oncologyarticle
  24. Camrelizumab plus taxanes and cisplatin (TP) chemotherapy or TP chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma2023Research Squarepreprint
  25. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncologyconference-abstract
  26. Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation2023Research Squarepreprint
  27. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)2023Journal of Clinical Oncologyconference-abstract
  28. Standard Therapy vs. Individualized Therapy in Elderly Locally Advanced Nasopharyngeal Carcinoma: A Real-World Study2023International Journal of Radiation Oncology*Biology*Physicsarticle
  29. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Researchconference-abstract
  30. Long-term outcomes of nasopharyngeal carcinoma by Epstein-Barr virus status in the Chinese population: a multicenter investigation2022Research Squarepreprint
  31. Penpulimab plus gemcitabine in combination with cisplatin or anlotinib as first-line treatment for metastatic nasopharyngeal carcinoma (M NPC): A phase II study.2022Journal of Clinical Oncologyconference-abstract
  32. AccuLearning: A User-Friendly Deep Learning Auto-Segmentation Platform for Radiotherapy2021International Journal of Radiation Oncology*Biology*Physicsarticle
  33. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncologyconference-abstract
  34. Patterns of Local-Regional Relapse Following Intensity-Modulated Radiotherapy for Patients With Nasopharyngeal Carcinoma2021International Journal of Radiation Oncology*Biology*Physicsarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 8 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 2220242025: 332025

5 hospitals in Wuhan for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07403435

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  2. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesNeoadjuvant & combined treatmentImmunotherapyRadiotherapy
Departments in papersRadiology / nuclear medicineGastroenterology / hepatology
Papers it led8
  1. NCF2 drives tumor progression and metastasis through NR2F2/LATS2/YAP1 axis in esophageal squamous cell carcinoma.2025Cancer letters
  2. The crossroads of inflammation and nutrition: predicting neoadjuvant immunochemotherapy efficacy in esophageal squamous cell carcinoma patients.2025Frontiers in immunologyFree full text
  3. Neoadjuvant chemoradiotherapy plus sequential tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): A single-arm, bicentric, phase 2 trial.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  4. CT-based delta-radiomics for predicting pathological response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma: a multicenter study.2024BMC medical imagingFree full text
  5. Efficacy, safety, and prognostic modeling in neoadjuvant immunotherapy for esophageal squamous cell carcinoma.2024International immunopharmacology
  6. Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial.2023BMC cancerFree full text
  7. Cetuximab enhances radiosensitivity of esophageal squamous cell carcinoma cells by G2/M cycle arrest and DNA repair delay through inhibiting p-EGFR and p-ERK.2023Thoracic cancerFree full text
  8. Exploration of an effective training system for diagnosis of superficial esophageal squamous cell carcinoma with magnifying narrow-band imaging: Prospective research.2021Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society
All its trials on ClinicalTrials.gov, any status13
  1. Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCCNot yet recruitingNCT07403435Lead sponsorPhase 2Start 2026-02
  2. Chemoradiotherapy Plus Immunotherapy Followed by Surgery for Esophageal CancerStatus unknownNCT04776590Lead sponsorPhase 2Start 2021-01
  3. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  4. A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Study sitePhase 1Start 2024-08
  5. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  6. Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell CarcinomaCompletedNCT04974047Study sitePhase 2Start 2021-08
  7. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  8. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownNCT05602792Study sitePhase 1/Phase 2Start 2020-04
  9. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  10. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  11. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  12. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  13. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT01232374Study sitePhase 2Start 2010-09
More papers found outside PubMed (not counted)12
  1. 2125P A phase II study of simmitinib in combination with liposomal irinotecan for second-line treatment of advanced esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  2. Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis2025Journal of Clinical Oncologyconference-abstract
  3. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  4. Neoadjuvant Chemoradiotherapy plus Sequential Tislelizumab Followed by Surgery for Esophageal Carcinoma (CRISEC study): A Prospective, Single-Arm, Phase II Trial2024International Journal of Radiation Oncology*Biology*Physicsarticle
  5. 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)2023Annals of Oncologyarticle
  6. Effectiveness and safety of camrelizumab in advanced esophageal cancer: A prospective multicenter observational cohort studies (ESCORT-RWS).2023Journal of Clinical Oncologyconference-abstract
  7. KC1036, a novel oral multi-kinase inhibitor, in patients with previously treated advanced esophageal squamous cell carcinoma (ESCC): Results from a multicenter, single-arm phase II trial.2023Journal of Clinical Oncologyconference-abstract
  8. 163P Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma: An interim analysis of the prospective, single-arm, phase II trial2022Immuno-Oncology Technologyarticle
  9. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  10. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  11. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  12. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 144 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 1.0%.

Papers led
144
2021–2025
Trials led
9
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 191920212022: 313120222023: 353520232024: 353520242025: 22222025

6 hospitals in Wuhan for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
    Phase
    Phase 2
    Started
    2026-10
    Registry
    NCT07776080

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  2. Recruiting
    Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)
    Phase
    Not given
    Started
    2025-07
    Registry
    NCT07059936

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  3. Recruiting
    Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07235410

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  4. Recruiting
    HAIC (Hepatic Artery Infusion Chemotherapy,HAIC)Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2024-01
    Registry
    NCT06244225

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  5. Recruiting
    Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular Carcinoma
    Phase
    Early phase 1
    Started
    2023-09
    Registry
    NCT06383520

    Age 18 years to 65 years (registered criteria)

    Led by Union HospitalWuhan

  6. Not yet recruiting
    Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular Carcinoma
    Phase
    Early phase 1
    Started
    2026-01
    Registry
    NCT07352345

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  7. Recruiting
    A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07052253

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhan

  8. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  9. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  10. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  11. Not yet recruiting
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07010588

    Age 18 years to 75 years (registered criteria)

    Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesLocal treatment (ablation, TACE, HAIC)Immunotherapy & targeted drugsRecurrence & prognosis
Departments in papersRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyPathology / laboratory medicine
Papers it led144
  1. Recent Advances in Embolic Agents for Transarterial Chemoembolization of Hepatocellular Carcinoma.2026Advanced healthcare materials
  2. Hyaluronidase optimizes TACE in hepatocellular carcinoma by remodeling tumor stroma and enhancing chemotherapy penetration.2026International journal of biological macromolecules
  3. Development and validation of a score model for predicting the risk of first esophagogastric variceal hemorrhage and mortality in patients with hepatocellular carcinoma.2025Annals of medicineFree full text
  4. RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma.2025BMC cancerFree full text
  5. Efficacy and safety analysis of D-TACE combined with lenvatinib in the treatment of hepatocellular carcinoma refractory to C-TACE.2025BMC gastroenterologyFree full text
  6. Long-term efficacy of transarterial chemoembolization in the treatment of recurrent hepatocellular carcinoma.2025BMC gastroenterologyFree full text
  7. Feasibility, efficacy, and safety of ventral caudal artery access for transarterial chemoembolization in a rat hepatocellular carcinoma model.2025BMC gastroenterologyFree full text
  8. Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.2025BMC medicineRCTFree full text
  9. Ellagic acid mediated pyroptosis in hepatocellular carcinoma via the ESR1/G6PD pathway.2025Biochemical pharmacology
  10. Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma.2025Cell death & diseaseFree full text
  11. STAT3 orchestrates immune dynamics in hepatocellular carcinoma: A pivotal nexus in tumor progression.2025Critical reviews in oncology/hematology
  12. Hepatic Artery Infusion Chemotherapy for Hepatocellular Carcinoma: Clinical Advancements.2025Current oncology (Toronto, Ont.)Free full text
  13. [68Ga]Ga-PSMA-617 PET/MRI for imaging patients suspected of hepatocellular carcinoma.2025European journal of nuclear medicine and molecular imaging
  14. Immunotherapy improved the efficacy of TACE or TACE plus MTTs in HCC patients: A meta-analysis.2025International immunopharmacology
  15. The Dual Role of TRADD in Liver Disease: From Cell Death Regulation to Inflammatory Microenvironment Remodeling.2025International journal of molecular sciencesFree full text
  16. Exosome-Delivered circFOXP1 Upregulates Autophagy and Promotes Hepatocellular Carcinoma Progression Through Its Encoded p196 Protein Targeting the KHDRBS3/ULK1 Axis.2025International journal of nanomedicineFree full text
  17. Protein Induced by Vitamin K Absence or Antagonist-II: Significantly Elevated in Obstructive Jaundice and Sepsis Patients Without Hepatocellular Carcinoma.2025Journal of clinical laboratory analysisFree full text
  18. COX-2/PGE2 axis blockade with celecoxib enhances anti-PD-1 efficacy by activating natural killer cells for residual hepatocellular carcinoma after radiofrequency ablation.2025Journal of experimental & clinical cancer research : CRFree full text
  19. Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial.2025Nature communicationsFree full text
  20. A glucose kinase-independent HK2 activity prevents TNF-induced cell death by phosphorylating RIPK1.2025Nature communicationsFree full text
  21. [Expression of Concern] Reciprocal negative feedback loop between EZH2 and miR‑101‑1 contributes to miR‑101 deregulation in hepatocellular carcinoma.2025Oncology reportsFree full text
  22. The efficacy and safety analysis of D-TACE combined with donafenib and tislelizumab in recurrent hepatocellular carcinoma after surgery.2025Scientific reportsFree full text
  23. Prognostic impact of extracellular volume fraction derived from equilibrium contrast-enhanced CT in HCC patients receiving immune checkpoint inhibitors.2025Scientific reportsFree full text
  24. Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular2025World journal of surgical oncologyFree full text
  25. Efficacy Analysis of PTCD + TACE vs PTCD + Apatinib in the Treatment of HCC with Obstructive Jaundice: A Retrospective Study.2024Anti-cancer agents in medicinal chemistry
  26. Construction of a random survival forest model based on a machine learning algorithm to predict early recurrence after hepatectomy for adult hepatocellular carcinoma.2024BMC cancerFree full text
  27. Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma.2024BMC cancerFree full text
  28. Predictors and risk factors of bile duct injury after transcatheter arterial chemoembolization for hepatocellular carcinoma.2024BMC cancerFree full text
  29. Nomograms established for predicting microvascular invasion and early recurrence in patients with small hepatocellular carcinoma.2024BMC cancerFree full text
  30. Utility and predictive value of the CRAFITY score in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus tyrosine kinase inhibitors and PD-1 inhibitor.2024BMC cancerFree full text
  31. Embolization alone is as effective as TACE for unresectable HCC: systematic review and meta-analysis of randomized controlled trails.2024BMC gastroenterologyFree full text
  32. Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial.2024BMJ openFree full text
  33. Recent advances in hepatocellular carcinoma-targeted nanoparticles.2024Biomedical materials (Bristol, England)
  34. Parapharyngeal and maxillary metastasis in hepatocellular carcinoma as the first presentation: a rare case.2024Brazilian journal of otorhinolaryngologyFree full text
  35. Efficacy and Safety of TACE Combined with Regorafenib versus TACE Combined with Camrelizumab in Hepatocellular Carcinoma With Untreatable Progression After TACE Combined with Sorafenib Therapy: A Case Control Study.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  36. Deciphering the immunological and prognostic features of hepatocellular carcinoma through ADP-ribosylation-related genes analysis and identify potential therapeutic target ARFIP2.2024Cellular signalling
  37. Cell Cycle-Related LncRNA-Based Prognostic Model for Hepatocellular Carcinoma: Integrating Immune Microenvironment and Treatment Response.2024Current medical science
  38. Incidence, Risk Factors, and Prognosis of Patients with Hepatocellular Carcinoma and Brain Metastases.2024Current medical science
  39. TRAF2 decrease promotes the TGF-β-mTORC1 signal in MAFLD-HCC through enhancing AXIN1-mediated Smad7 degradation.2024FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  40. Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience.2024Frontiers in immunologyFree full text
  41. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.2024Frontiers in immunologyFree full text
  42. IL-22 signaling promotes sorafenib resistance in hepatocellular carcinoma via STAT3/CD155 signaling axis.2024Frontiers in immunologyFree full text
  43. Blocking TGFβR synergistically enhances anti-tumor effects of anti-PD-1 antibody in a mouse model of incomplete thermal ablation.2024International immunopharmacology
  44. Radiofrequency hyperthermia enhances the effect of OK-432 for Hepatocellular carcinoma by activating of TLR4-cGAS-STING pathway.2024International immunopharmacology
  45. Exosomal SLC16A1-AS1-induced M2 macrophages polarization facilitates hepatocellular carcinoma progression.2024International journal of biological sciencesFree full text
  46. The m6A modification-mediated positive feedback between glycolytic lncRNA SLC2A1-DT and c-Myc promotes tumorigenesis of hepatocellular carcinoma.2024International journal of biological sciencesFree full text
  47. Drug-Loaded Tumor-Derived Microparticles Elicit CD8+ T Cell-Mediated Anti-Tumor Response in Hepatocellular Carcinoma.2024International journal of nanomedicineFree full text
  48. Synergistic Effects of Nanoscale CaO2 Combined with PD-1 Inhibitors in the Treatment of Hepatocellular Carcinoma: A Promising Combination.2024International journal of nanomedicineFree full text
  49. Relaxin combined with transarterial chemoembolization achieved synergistic effects and inhibited liver cancer metastasis in a rabbit VX2 model.2024Journal of cancer research and clinical oncologyFree full text
  50. Multi-Omics Profiling and Experimental Verification of Lysosomes-Related Genes in Hepatocellular Carcinoma.2024Journal of cellular and molecular medicineFree full text
  51. The liquid-liquid phase separation signature predicts the prognosis and immunotherapy response in hepatocellular carcinoma.2024Journal of cellular and molecular medicineFree full text
  52. Enhanced efficacy of combined VEGFR peptide-drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma.2024Scientific reportsFree full text
  53. Prognosis and chemotherapy drug sensitivity in liver hepatocellular carcinoma through a disulfidptosis-related lncRNA signature.2024Scientific reportsFree full text
  54. Ablation alone is noninferior to radiotherapy plus ablation in the patients with early-stage hepatocellular carcinoma: a population-based study.2024Scientific reportsFree full text
  55. Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies.2024Targeted oncology
  56. Drug-eluting bead transarterial chemoembolization combined with apatinib/camrelizumab for the treatment of advanced hepatocellular carcinoma with hepatic arterioportal shunts.2024The British journal of radiologyFree full text
  57. Sorafenib plus transcatheter arterial chemoembolization with or without camrelizumab for the treatment of intermediate and advanced hepatocellular carcinoma.2024The British journal of radiologyFree full text
  58. Decreased lncRNA HNF4A-AS1 facilitates resistance to sorafenib-induced ferroptosis of hepatocellular carcinoma by reprogramming lipid metabolism.2024TheranosticsFree full text
  59. Comparison of laparoscopic hepatectomy and radiofrequency ablation for small hepatocellular carcinoma patients: a SEER population-based propensity score matching study.2024Updates in surgeryFree full text
  60. Ferroptosis-Enhanced Immunotherapy with an Injectable Dextran-Chitosan Hydrogel for the Treatment of Malignant Ascites in Hepatocellular Carcinoma.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  61. Efficacy and Safety of Lobaplatin-TACE in the Treatment of Primary Hepatocellular Carcinoma: A Retrospective Study.2023Anti-cancer agents in medicinal chemistryFree full text
  62. A rare case of hepatocellular carcinoma supplied by the left internal mammary artery treated with transarterial chemoembolization.2023Asian journal of surgery
  63. Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study.2023BMC cancerFree full text
  64. Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study.2023BMC cancerFree full text
  65. TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma.2023BMC cancerFree full text
  66. Nuclear respiratory factor 1 drives hepatocellular carcinoma progression by activating LPCAT1-ERK1/2-CREB axis.2023Biology directFree full text
  67. Synergistic effect of OK-432 in combination with an anti-PD-1 antibody for residual tumors after radiofrequency ablation of hepatocellular carcinoma.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  68. Shp2 Deficiency in Kupffer Cells and Hepatocytes Aggravates Hepatocarcinogenesis by Recruiting Non-Kupffer Macrophages.2023Cellular and molecular gastroenterology and hepatologyFree full text
  69. Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.2023Clinical cancer research : an official journal of the American Association for Cancer ResearchRCT
  70. Safety and Effectiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Aged Greater versus Less Than 80 Years.2023Clinical interventions in agingFree full text
  71. Transarterial chemoembolization failure in patients with hepatocellular carcinoma: Incidence, manifestation and risk factors.2023Clinics and research in hepatology and gastroenterology
  72. Comprehensive Treatment Uncertainty Analysis and PTV Margin Estimation for Fiducial Tracking in Robotic Liver Stereotactic Body Radiation Therapy.2023Current medical science
  73. Liver Transplantation Outcomes of HBV-, HCV-, and Alcohol-induced Hepatocellular Carcinoma in the United States: Analysis of National Inpatient Samples.2023Current medical science
  74. Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma.2023European journal of medical researchFree full text
  75. Study on anxiety and depression in elderly patients with malignant liver tumor undergoing hepatectomy.2023European journal of medical researchFree full text
  76. Validation and utility of HepG2 xenograft model for hepatocellular carcinoma.2023European journal of nuclear medicine and molecular imaging
  77. [177Lu]Lu-PSMA-617 theranostic probe for hepatocellular carcinoma imaging and therapy.2023European journal of nuclear medicine and molecular imaging
  78. A gadoxetic-acid enhancement flux analysis of small liver nodules (≤2 cm) in patients at high risk of hepatocellular carcinoma.2023European journal of radiology
  79. Contrast-enhanced CT parameters predict short-term tumor response in patients with hepatocellular carcinoma who received sequential combined anti-angiogenesis and immune checkpoint inhibitor treatment.2023European journal of radiology
  80. A novel liver zonation phenotype-associated molecular classification of hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  81. Radiation therapy in the era of immune treatment for hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  82. Diabetes and the risk of cirrhosis and HCC: An analysis of the UK Biobank.2023Hepatology communicationsFree full text
  83. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.2023International immunopharmacology
  84. FARSB Facilitates Hepatocellular Carcinoma Progression by Activating the mTORC1 Signaling Pathway.2023International journal of molecular sciencesFree full text
  85. Deficiency of Carbamoyl Phosphate Synthetase 1 Engenders Radioresistance in Hepatocellular Carcinoma via Deubiquitinating c-Myc.2023International journal of radiation oncology, biology, physics
  86. LncRNA FTO-IT1 promotes glycolysis and progression of hepatocellular carcinoma through modulating FTO-mediated N6-methyladenosine modification on GLUT1 and PKM2.2023Journal of experimental & clinical cancer research : CRFree full text
  87. Injectable hydrogel loaded with lysed OK-432 and doxorubicin for residual liver cancer after incomplete radiofrequency ablation.2023Journal of nanobiotechnologyFree full text
  88. Efficacy, mechanism, and safety of melatonin-loaded on thermosensitive nanogels for rabbit VX2 tumor embolization: A novel design.2023Journal of pineal research
  89. Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma.2023MedicineRCTFree full text
  90. Efficacy and safety analysis of dexamethasone + palonosetron in prevention of post-embolization syndrome after D-TACE: A retrospective study.2023MedicineFree full text
  91. Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles.2023OncoimmunologyFree full text
  92. A novel fatty acid metabolism-related gene prognostic signature and candidate drugs for patients with hepatocellular carcinoma.2023PeerJFree full text
  93. Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: an updated meta-analysis.2023Scientific reportsFree full text
  94. Pyogenic liver abscess in non-liver cancer patients and liver cancer patients treated with TACE: Etiological characteristics, treatment, and outcome analysis.2023The Kaohsiung journal of medical sciencesFree full text
  95. The role of gadoxetic acid-enhanced MRI features for predicting microvascular invasion in patients with hepatocellular carcinoma.2022Abdominal radiology (New York)
  96. The safety and efficacy of percutaneous ethanol injection in the treatment of tumor thrombus in advanced hepatocellular carcinoma with portal vein tumor thrombus.2022Abdominal radiology (New York)
  97. Nanoscale CaO2 materials for synergistic transarterial chemoembolization in a VX2 orthotopic rabbit liver cancer model.2022Acta biomaterialia
  98. Ferroptosis-related long non-coding RNA signature predicts the prognosis of hepatocellular carcinoma.2022AgingFree full text
  99. Renal and hepatic artery embolization with Pickering gel emulsion of lipiodol in rabbit.2022BMC cancerFree full text
  100. MYBL2 regulates de novo purine synthesis by transcriptionally activating IMPDH1 in hepatocellular carcinoma cells.2022BMC cancerFree full text
  101. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.2022BMC cancerFree full text
  102. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma.2022BMC cancerFree full text
  103. Circ_0000591 served as endogenous RNA for miR-326 to promote progression of cholangiocarcinoma via the TLR4/MyD88/IL6 axis.2022Biochemical and biophysical research communications
  104. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.2022Cancer control : journal of the Moffitt Cancer CenterFree full text
  105. Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE.2022Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  106. Comparison of the Efficacy Among Transcatheter Arterial Chemoembolization (TACE)-Radiofrequency Ablation Plus Apatinib, TACE Plus Apatinib, and TACE Alone for Hepatocellular Carcinoma: A Retrospective Study.2022Cardiovascular and interventional radiology
  107. S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway.2022Cell reports
  108. Comparison of DEB-TACE and cTACE for the initial treatment of unresectable hepatocellular carcinoma beyond up-to-seven criteria: A single-center propensity score matching analysis.2022Clinics and research in hepatology and gastroenterology
  109. Transarterial Chemoembolization Combined with Apatinib for Treatment of Advanced Hepatocellular Carcinoma: Analysis of Survival and Prognostic Factors.2022Current medical science
  110. Application of Intravoxel Incoherent Motion in the Evaluation of Hepatocellular Carcinoma after Transarterial Chemoembolization.2022Current oncology (Toronto, Ont.)Free full text
  111. Perioperative factors related to the prognosis of elderly patients with hepatocellular carcinoma.2022European journal of medical researchFree full text
  112. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617.2022European journal of nuclear medicine and molecular imagingFree full text
  113. Identification of a novel histone phosphorylation prognostic signature in hepatocellular carcinoma based on bulk and single-cell RNA sequencing.2022Frontiers in endocrinologyFree full text
  114. Molecular Imaging of Tumor Microenvironment to Assess the Effects of Locoregional Treatment for Hepatocellular Carcinoma.2022Hepatology communicationsFree full text
  115. The impact of particulate matter 2.5 on the risk of hepatocellular carcinoma: a meta-analysis.2022International archives of occupational and environmental health
  116. Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6.2022International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  117. Association of Adjuvant Radiation Therapy With Long-Term Overall and Recurrence-Free Survival After Hepatectomy for Hepatocellular Carcinoma: A Multicenter Propensity-Matched Study.2022International journal of radiation oncology, biology, physics
  118. Enhanced efficacy of direct immunochemotherapy for hepatic cancer with image-guided intratumoral radiofrequency hyperthermia.2022Journal for immunotherapy of cancerFree full text
  119. Research Progress in Alpha-fetoprotein-induced Immunosuppression of Liver Cancer.2022Mini reviews in medicinal chemistry
  120. Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor.2022Molecular pharmaceutics
  121. The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus.2022Scientific reportsFree full text
  122. Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression.2022Technology in cancer research & treatmentFree full text
  123. Liver abscess after drug-eluting bead chemoembolization in patients with metastatic hepatic tumors.2022The British journal of radiologyFree full text
  124. Crosstalk between macrophage-derived PGE2 and tumor UHRF1 drives hepatocellular carcinoma progression.2022TheranosticsFree full text
  125. Effect of perioperative factors on the prognosis of patients with hepatocellular carcinoma who underwent hepatectomy.2022Turkish journal of medical sciencesFree full text
  126. Mechanism and risk factors of nausea and vomiting after TACE: a retrospective analysis.2021BMC cancerFree full text
  127. Integrated analysis of the functions and prognostic values of RNA binding proteins in hepatocellular carcinoma.2021BMC gastroenterologyFree full text
  128. Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: a retrospective analysis.2021BMC gastroenterologyFree full text
  129. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study.2021BMC gastroenterologyFree full text
  130. Development of a novel lipid metabolism-based risk score model in hepatocellular carcinoma patients.2021BMC gastroenterologyFree full text
  131. MicroRNA miR-495 regulates the development of Hepatocellular Carcinoma by targeting C1q/tumor necrosis factor-related protein-3 (CTRP3).2021BioengineeredFree full text
  132. Sublethal hyperthermia enhances anticancer activity of doxorubicin in chronically hypoxic HepG2 cells through ROS-dependent mechanism.2021Bioscience reportsFree full text
  133. The efficacy of radiofrequency ablation versus cryoablation in the treatment of single hepatocellular carcinoma: A population-based study.2021Cancer medicineFree full text
  134. Epigenetic and Immune-Cell Infiltration Changes in the Tumor Microenvironment in Hepatocellular Carcinoma.2021Frontiers in immunologyFree full text
  135. Efficacy of apatinib in patients with sorafenib-transarterial chemoembolization refractory hepatocellular carcinoma: a retrospective study.2021Hepatology international
  136. Transcatheter chemoembolization plus percutaneous radiofrequency ablation versus laparoscopic radiofrequency ablation: improved outcome for inoperable hepatocellular carcinoma.2021International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  137. Single sample scoring of hepatocellular carcinoma: A study based on data mining.2021International journal of immunopathology and pharmacologyFree full text
  138. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma.2021International journal of medical sciencesFree full text
  139. Downregulation of hsa_circ_0074854 Suppresses the Migration and Invasion in Hepatocellular Carcinoma via Interacting with HuR and via Suppressing Exosomes-Mediated Macrophage M2 Polarization.2021International journal of nanomedicineFree full text
  140. Lenvatinib and Cu2-xS nanocrystals co-encapsulated in poly(D,L-lactide-co-glycolide) for synergistic chemo-photothermal therapy against advanced hepatocellular carcinoma.2021Journal of materials chemistry. B
  141. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.2021Journal of nanobiotechnologyFree full text
  142. Systemic immune-inflammation index predicts postoperative acute kidney injury in hepatocellular carcinoma patients after hepatectomy.2021MedicineFree full text
  143. Value of gadoxetic acid-enhanced MR imaging and DWI in classification, characterization and confidence in diagnosis of solid focal liver lesions.2021Scandinavian journal of gastroenterology
  144. Quantitative dual-energy CT for evaluating hepatocellular carcinoma after transarterial chemoembolization.2021Scientific reportsFree full text
All its trials on ClinicalTrials.gov, any status25
  1. Head to Head, Prospective, Open Label Multicenter Study on the Diagnostic Efficacy of GPC3 Targeted PET Imaging and Enhanced Magnetic Resonance Imaging for Hepatocellular CarcinomaNot yet recruitingNCT07352345Lead sponsorEarly phase 1Start 2026-01
  2. Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor ThrombusRecruitingNCT07776080Lead sponsorPhase 2Start 2026-10
  3. Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACERecruitingNCT07235410Lead sponsorStart 2025-11
  4. Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)RecruitingNCT07059936Lead sponsorStart 2025-07
  5. HAIC (Hepatic Artery Infusion Chemotherapy,HAIC)Plus Sintilimab and Donafenib in the First-line Treatment of Unresectable Hepatocellular CarcinomaRecruitingNCT06244225Lead sponsorPhase 2Start 2024-01
  6. Study on the Clinical Application Value of PET Imaging Targeting GPC3 in Hepatocellular CarcinomaRecruitingNCT06383520Lead sponsorEarly phase 1Start 2023-09
  7. Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular CarcinomaStatus unknownNCT05617430Lead sponsorPhase 2Start 2022-11
  8. Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular CarcinomaStatus unknownNCT05006326Lead sponsorN/AStart 2021-08
  9. The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label StudyStatus unknownNCT04909866Lead sponsorPhase 2/Phase 3Start 2021-01
  10. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  11. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High RiskNot yet recruitingNCT07010588Study siteN/AStart 2025-06
  12. A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.RecruitingNCT07052253Study sitePhase 2Start 2025-07
  13. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  14. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  15. Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphereActive, not recruitingNCT06900543Study sitePhase 3Start 2025-04
  16. A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular CarcinomaTerminatedNCT05653427Study sitePhase 2Start 2022-12
  17. Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)CompletedNCT04740307Study sitePhase 2Start 2021-03
  18. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Study sitePhase 3Start 2019-06
  19. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  20. Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)CompletedNCT03867084Study sitePhase 3Start 2019-05
  21. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  22. Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Study sitePhase 3Start 2018-12
  23. Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Study sitePhase 2Start 2018-04
  24. Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local AblationStatus unknownNCT03356236Study siteStart 2018-04
  25. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Study sitePhase 3Start 2017-12

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 78 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.8%.

Papers led
78
2021–2025
Trials led
20
any status, ClinicalTrials.gov
Open trials led
9
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 121220212022: 161620222023: 111120232024: 202020242025: 15152025

5 hospitals in Wuhan for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 15

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    CT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric Cancer
    Phase
    Not given
    Started
    2026-04
    Registry
    NCT07776067

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  2. Recruiting
    A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06685887

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  3. Recruiting
    Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07301814

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  4. Recruiting
    Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2025-07
    Registry
    NCT07920224

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  5. Recruiting
    Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
    Phase
    Phase 2
    Started
    2024-05
    Registry
    NCT06487429

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  6. Recruiting
    Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06826079

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  7. Not yet recruiting
    Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort Study
    Phase
    Phase 2
    Started
    2026-09
    Registry
    NCT07872696

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  8. Not yet recruiting
    Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors
    Phase
    N/A
    Started
    2025-10
    Registry
    NCT07172503

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  9. Not yet recruiting
    Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
    Phase
    Phase 4
    Started
    2024-07
    Registry
    NCT05498766

    Age 18 years to 75 years (registered criteria)

    Led by Union Hospital; 1 listed hospital as study siteQingdao, Wuhan

  10. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  11. Recruiting
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07552402

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Nanning, Shanghai, Shijiazhuang, Suzhou, Wuhan, Yinchuan

  12. Recruiting
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
    Phase
    Phase 1
    Started
    2025-07
    Registry
    NCT07066657

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Shanghai, Wuhan, Zhengzhou

  13. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  14. Recruiting
    A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2022-01
    Registry
    NCT05150691

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wenzhou, Wuhan, Wuxi, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

  15. Recruiting
    A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
    Phase
    Phase 1
    Started
    2022-06
    Registry
    NCT05365581

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunotherapy & targeted drugsPeritoneal spread & advanced diseaseImaging & AI
Departments in papersGastroenterology / hepatologyPathology / laboratory medicineRadiology / nuclear medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led78
  1. Three-Year Follow-Up of Neoadjuvant Tislelizumab with Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Revealing Cancer-Associated Fibroblast Heterogeneity Corresponding to PD-1 Blockade Efficacy.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Oxidative Stress Inflammation Score is the Optimal Inflammatory Prognostic Indicator for Patients with Locally Advanced Gastric Cancer Receiving Neoadjuvant Immunochemotherapy: A Multicenter Retrospective Cohort Study.2026Annals of surgical oncology
  3. Association of different autoimmune diseases with gastric cancer incidence and risk: a global population-based analysis.2026International journal of surgery (London, England)
  4. Prognostic value of combined pathological response in primary tumor and lymph nodes after neoadjuvant chemoimmunotherapy for locally advanced gastric cancer.2026Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  5. Nortriptyline Inhibits Lysosomal Exocytosis-Mediated SASP During Gastric Cancer Progression via Targeting HOXA1-PITX2 Phase Separation.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  6. Multi-omics analysis reveals disrupted gut microbiota and metabolism in gastric cancer patients with high SIRI.2025BMC cancerFree full text
  7. Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis.2025BMC cancerFree full text
  8. Lipid accumulation product and visceral adiposity index as independent predictors of long-term survival after gastric cancer immunotherapy.2025BMC cancerFree full text
  9. Impact of intraoperative explanation combined with surgical video review on anatomy learning in laparoscopic distal gastrectomy.2025BMJ openRCTFree full text
  10. Impaired ARID1A expression attenuated the immune response in gastric cancer via histone acetylation.2025Clinical epigeneticsFree full text
  11. Prognostic value of [68Ga]Ga-FAPI-04 PET in patients with newly diagnosed gastric carcinoma.2025European journal of nuclear medicine and molecular imaging
  12. Which surrogate endpoint best predict survival in locally advanced gastric cancer patients undergoing neoadjuvant chemoimmunotherapy followed by surgery? A multicenter retrospective study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  13. Establishment of an anaplastic stratification signature for gastric cancer based on diverse regulated cell-death.2025Frontiers in immunologyFree full text
  14. Prognostic value of Naples prognostic score for locally advanced gastric cancer after neoadjuvant chemoimmunotherapy.2025Future oncology (London, England)Free full text
  15. SNORA37/CMTR1/ELAVL1 feedback loop drives gastric cancer progression via facilitating CD44 alternative splicing.2025Journal of experimental & clinical cancer research : CRFree full text
  16. Effectiveness of Snare Traction-Facilitated Endoscopic Resection for Gastric Submucosal Tumors ≥ 2 cm: A Propensity Score-Matched Study.2025Journal of laparoendoscopic & advanced surgical techniques. Part A
  17. USP29 and SMURF1 orchestrate FSP1-mediated ferroptosis suppression to facilitate chemoresistance in gastric cancer.2025Nature communicationsFree full text
  18. Advancements in non-invasive diagnosis of gastric cancer.2025World journal of gastroenterologyFree full text
  19. Preoperative serum magnesium level as a prognostic and predictive biomarker in locally advanced gastric cancer patients receiving neoadjuvant immunochemotherapy.2025World journal of surgical oncologyFree full text
  20. ASO Author Reflections: Neoadjuvant Chemotherapy Combined with Immunotherapy is a Promising Strategy for Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.2024Annals of surgical oncology
  21. Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial.2024Annals of surgical oncology
  22. Lymph node ratio is a prognostic indicator for locally advanced gastric cancer after neoadjuvant immunochemotherapy.2024BMC gastroenterologyFree full text
  23. Interleukin-6 on postoperative day three as an early predictor of infections following laparoscopic gastric cancer resection.2024BMC surgeryFree full text
  24. Inhibition of glycolysis enhances the efficacy of immunotherapy via PDK-mediated upregulation of PD-L1.2024Cancer immunology, immunotherapy : CIIFree full text
  25. Gut Roseburia is a protective marker for peritoneal metastasis of gastric cancer.2024Cancer medicineFree full text
  26. EIF2S2 transcriptionally upregulates HIF1α to promote gastric cancer progression via activating PI3K/AKT/mTOR pathway.2024Carcinogenesis
  27. Gamma-glutamyl transferase secreted by Helicobacter pylori promotes the development of gastric cancer by affecting the energy metabolism and histone methylation status of gastric epithelial cells.2024Cell communication and signaling : CCSFree full text
  28. Human gastric cancer progression and stabilization of ATG2B through RNF5 binding facilitated by autophagy-associated CircDHX8.2024Cell death & diseaseFree full text
  29. Immune checkpoints signature-based risk stratification for prognosis of patients with gastric cancer.2024Cellular signalling
  30. Case report metastatic SMARCB1 (INI1)-deficient gastric undifferentiated carcinoma in pleural effusion: A case report and literature review.2024Cytopathology : official journal of the British Society for Clinical Cytology
  31. CircMTA2 Drives Gastric Cancer Progression through Suppressing MTA2 Degradation via Interacting with UCHL3.2024International journal of molecular sciencesFree full text
  32. A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.2024International journal of surgery (London, England)Free full text
  33. Impact of Helicobacter pylori on immunotherapy in gastric cancer.2024Journal for immunotherapy of cancerFree full text
  34. The effect of surgery and metastatic risk prediction in patients with gastrointestinal tract signet-ring cell carcinoma.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  35. Re-analysis of single cell and spatial transcriptomics data reveals B cell landscape in gastric cancer microenvironment and its potential crosstalk with tumor cells for clinical prognosis.2024Journal of translational medicineFree full text
  36. Prognosis of EBV-positive gastric cancer with lymphoid stroma: systematic review and meta-analysis.2024Scandinavian journal of gastroenterology
  37. Helicobacter pylori CagA mediated mitophagy to attenuate the NLRP3 inflammasome activation and enhance the survival of infected cells.2024Scientific reportsFree full text
  38. Analysis of clinicopathological characteristics and prognosis on primary gastric adenosquamous carcinoma.2024Scientific reportsFree full text
  39. Identification of a lipid homeostasis-related gene signature for predicting prognosis, immunity, and chemotherapeutic effect in patients with gastric cancer.2024Scientific reportsFree full text
  40. Tumor size as a significant prognostic factor in T1 gastric cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis.2023BMC gastroenterologyFree full text
  41. Epigenetic and Tumor Microenvironment for Prognosis of Patients with Gastric Cancer.2023BiomoleculesFree full text
  42. Microvesicles from bone marrow-derived mesenchymal stem cells promote Helicobacter pylori-associated gastric cancer progression by transferring thrombospondin-2.2023Cell communication and signaling : CCSFree full text
  43. Prediction of HER2 status via random forest in 3257 Chinese patients with gastric cancer.2023Clinical and experimental medicine
  44. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort.2023Frontiers in immunologyFree full text
  45. Exosome-Delivered circSTAU2 Inhibits the Progression of Gastric Cancer by Targeting the miR-589/CAPZA1 Axis.2023International journal of nanomedicineFree full text
  46. The impact of surgery and survival prediction in patients with gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.2023International journal of surgery (London, England)Free full text
  47. circ-hnRNPU inhibits NONO-mediated c-Myc transactivation and mRNA stabilization essential for glycosylation and cancer progression.2023Journal of experimental & clinical cancer research : CRFree full text
  48. Bone mesenchymal stem cells promote gastric cancer progression through TGF-β1/Smad2 positive feedback loop.2023Life sciences
  49. Clinicopathological characteristics of mixed neuroendocrine-non-neuroendocrine neoplasms in gastrointestinal tract.2023Pathology, research and practice
  50. Laparoscopic versus open gastrectomy for locally advanced gastric cancer after neoadjuvant chemotherapy: a comprehensive contrastive analysis with propensity score matching.2023World journal of surgical oncologyFree full text
  51. A radiomics model predicts the response of patients with advanced gastric cancer to PD-1 inhibitor treatment.2022AgingRCTFree full text
  52. Comparative Study of the Efficacy and Safety of Radical Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy in Locally Advanced Gastric Cancer: A Propensity Score-Matching Analysis.2022Annals of surgical oncology
  53. Therapeutic targeting of the USP2-E2F4 axis inhibits autophagic machinery essential for zinc homeostasis in cancer progression.2022AutophagyFree full text
  54. Identification of miRNA biomarkers for stomach adenocarcinoma.2022BMC bioinformaticsFree full text
  55. A dynamic predictive nomogram of long-term survival in primary gastric lymphoma: a retrospective study.2022BMC gastroenterologyFree full text
  56. Effect of Postoperative ω-3 Fatty Acid Immunonutritional Therapy on NK Cell Gene Methylation in Elderly Patients with Gastric Cancer.2022Current medical scienceRCT
  57. Long noncoding RNA SNHG8 promotes chemoresistance in gastric cancer via binding with hnRNPA1 and stabilizing TROY expression.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  58. A new therapy for refractory gastric cancer bleeding: endoscopic ultrasound-guided lauromacrogol injection.2022Endoscopy
  59. The risk of aspirin induced postoperative hemorrhage: a systematic review and meta-analysis.2022Expert review of gastroenterology & hepatology
  60. LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  61. Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting ARID1A deficiency.2022GutFree full text
  62. Gamma-glutamyltransferase of Helicobacter pylori alters the proliferation, migration, and pluripotency of mesenchymal stem cells by affecting metabolism and methylation status.2022Journal of microbiology (Seoul, Korea)
  63. 68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT.2022Journal of nuclear medicine : official publication, Society of Nuclear MedicineFree full text
  64. Efficacy of local hemostatic agents after endoscopic submucosal dissection: a meta-analysis.2022Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  65. Safety and feasibility of laparoscopy-assisted surgery for gastrointestinal stromal tumors larger than 5 cm: Results of a retrospective, single-center series of 1,802 consecutive patients.2022Surgery
  66. Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy.2022World journal of surgical oncologyFree full text
  67. THBS4/integrin α2 axis mediates BM-MSCs to promote angiogenesis in gastric cancer associated with chronic Helicobacter pylori infection.2021AgingFree full text
  68. The New American Joint Committee on Cancer T staging system for stomach: increased complexity without clear improvement in predictive accuracy for endoscopic ultrasound.2021BMC gastroenterologyFree full text
  69. Bone marrow-derived mesenchymal stem cells promote Helicobacter pylori-associated gastric cancer progression by secreting thrombospondin-2.2021Cell proliferationFree full text
  70. A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report.2021Frontiers in immunologyFree full text
  71. CircGSK3B promotes RORA expression and suppresses gastric cancer progression through the prevention of EZH2 trans-inhibition.2021Journal of experimental & clinical cancer research : CRFree full text
  72. Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells.2021Journal of experimental & clinical cancer research : CRFree full text
  73. The Gamma-glutamyltransferase gene of Helicobacter pylori can promote gastric carcinogenesis by activating Wnt signal pathway through up-regulating TET1.2021Life sciences
  74. The Potential Role of IL1RAP on Tumor Microenvironment-Related Inflammatory Factors in Stomach Adenocarcinoma.2021Technology in cancer research & treatmentFree full text
  75. Procalcitonin as an Early Predictor of Intra-abdominal Infections Following Gastric Cancer Resection.2021The Journal of surgical research
  76. PLAGL2 promotes the proliferation and migration of gastric cancer cells via USP37-mediated deubiquitination of Snail1.2021TheranosticsFree full text
  77. Plexiform angiomyxoid myofibroblastic tumor treated by endoscopic submucosal dissection: A case report and review of the literature.2021World journal of gastroenterologyFree full text
  78. Fecal Streptococcus Alteration Is Associated with Gastric Cancer Occurrence and Liver Metastasis.2021mBioFree full text
Chinese-language papers (not in the count)4
  1. [Application of totally laparoscopic right thoracic esophagojejunostomy in adenocarcinoma of the esophagogastric junction (AEG) surgery].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Safety evaluation of hyperthermic intraperitoneal chemotherapy in patients with local advanced gastric cancer after radical resection for prevention of peritoneal metastasis].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Pay attention to misdiagnosis and differential diagnosis of gastric gastrointestinal stromal tumor].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status48
  1. Exploring the Efficacy of Ferrous Sulfate/Ferrous Succinate Combined With Serplulimab and SOX Regimen in Neoadjuvant Therapy for Gastric Cancer: A Prospective Cohort StudyNot yet recruitingNCT07872696Lead sponsorPhase 2Start 2026-09
  2. CT Imaging and Clinical Features to Predict Outcomes in Patients With Gastric CancerRecruitingNCT07776067Lead sponsorStart 2026-04
  3. Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant TumorsRecruitingNCT07301814Lead sponsorStart 2025-09
  4. Clinical Application of PET Imaging Targeting GPA33 in Malignant TumorsNot yet recruitingNCT07172503Lead sponsorN/AStart 2025-10
  5. A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal MetastasisRecruitingNCT06685887Lead sponsorPhase 2Start 2025-02
  6. Candonilimab Combined With Fruquintinib and Paclitaxel Albumin-Bound as Second-Line Treatment for Advanced Gastric or Gastro-esophageal Junction AdenocarcinomaRecruitingNCT07920224Lead sponsorPhase 2Start 2025-07
  7. Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric CancerRecruitingNCT06487429Lead sponsorPhase 2Start 2024-05
  8. Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer PatientsNot yet recruitingNCT05498766Lead sponsorPhase 4Start 2024-07
  9. Safety and Efficacy Study of Sorbitol With Neoadjuvant Chemotherapy Combined With Tirellizumab (PD-1 Inhibitor) in Patients With Locally Advanced Gastric CancerRecruitingNCT06826079Lead sponsorPhase 2Start 2024-11
  10. Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal MetastasisStatus unknownNCT06487715Lead sponsorPhase 2Start 2024-03
  11. Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction AdenocarcinomaStatus unknownNCT05625737Lead sponsorPhase 2Start 2022-09
  12. Artificial Intelligence System for Assessment of Tumor Risk and Diagnosis and TreatmentStatus unknownNCT05426135Lead sponsorStart 2022-06
  13. Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and TreatmentStatus unknownNCT06653478Lead sponsorStart 2022-06
  14. Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid TumorsStatus unknownNCT05527821Lead sponsorPhase 2Start 2022-09
  15. Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal ChemotherapyStatus unknownNCT04808466Lead sponsorPhase 2Start 2021-09
  16. Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 TherapyStatus unknownNCT05029453Lead sponsorPhase 4Start 2021-08
  17. Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJCStatus unknownNCT04890392Lead sponsorPhase 2Start 2021-01
  18. A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard TherapyStatus unknownNCT05202236Lead sponsorPhase 2Start 2021-10
  19. Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric CancerStatus unknownNCT04563975Lead (inferred)Phase 2Start 2020-07
  20. A Multicenter Clinical Trial on Laparoscopic Gastric Cancer Surgery Compared With Open SurgeryStatus unknownNCT02302794Lead (inferred)Phase 3Start 2014-08
  21. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  22. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric CancerRecruitingNCT07552402Study siteN/AStart 2026-06
  23. A Study of MRG007 (ARR-217) in Patients With Advanced Solid TumorsRecruitingNCT07066657Study sitePhase 1Start 2025-07
  24. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  25. A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid TumorsRecruitingNCT05150691Study sitePhase 1/Phase 2Start 2022-01
  26. A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic CancerRecruitingNCT05365581Study sitePhase 1Start 2022-06
  27. Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Study sitePhase 1/Phase 2Start 2025-01
  28. A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Study sitePhase 1Start 2024-08
  29. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  30. Development and Testing of a Social Cognitive Theory-based Dietary Behavioral Intervention in Gastric Cancer SurvivorsCompletedNCT04985084Study siteN/AStart 2022-01
  31. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  32. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  33. A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal CancersActive, not recruitingNCT05152147Study sitePhase 3Start 2021-12
  34. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  35. A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior TreatmentTerminatedNCT04178460Study sitePhase 1Start 2020-02
  36. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer DiagnosisStatus unknownNCT04440605Study siteStart 2020-07
  37. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction CancerCompletedNCT03941873Study sitePhase 1/Phase 2Start 2019-02
  38. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction CancerCompletedNCT04053205Study sitePhase 1/Phase 2Start 2019-11
  39. Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ CancerCompletedNCT04082364Study sitePhase 2/Phase 3Start 2019-09
  40. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  41. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric CancerStatus unknownNCT03273920Study siteN/AStart 2017-09
  42. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal CancerCompletedNCT02898077Study sitePhase 3Start 2017-03
  43. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  44. Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2Status unknownNCT02356276Study sitePhase 3Start 2015-05
  45. Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma SurgeryStatus unknownNCT02130752Study siteN/AStart 2014-10
  46. Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total GastrectomyStatus unknownNCT02110628Study sitePhase 3Start 2014-08
  47. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)Status unknownNCT01609309Study sitePhase 3Start 2012-09
  48. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Study sitePhase 2/Phase 3Start 2012-09

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

5 hospitals in Wuhan for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. Current trends and prospects of surgical techniques for hepatoblastoma.2024Cancer medicine
All its trials on ClinicalTrials.gov, any status1
  1. Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid BlastomaCompletedNCT06190574Lead sponsorStart 2021-07

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 2 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

18 hospitals in Wuhan for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Wuhan for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Predicting overall survival in chordoma patients using machine learning models: a web-app application.2023Journal of orthopaedic surgery and research
Earlier papers (2016–2020)1
  1. Giant chordoma in the thoracolumbar spine: a case report and literature review.2017European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 25 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
25
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 8820222023: 3320232024: 5520242025: 662025

31 hospitals in Wuhan for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Over half of these papers are lab or animal studies.

Papers it led25
  1. Immune-Modulating Dual-Targeted Nanomaterials for Low-Temperature Photothermal-Photodynamic-Chemodynamic Therapy of Osteosarcoma Targeting Tumor and Endothelial Cells.2025ACS nano
  2. Bioactive nanocomposite hydrogel enhances postoperative immunotherapy and bone reconstruction for osteosarcoma treatment.2025Biomaterials
  3. Cancer-associated Fibroblast-like Cells Promote Osteosarcoma Metastasis by Upregulation of Phosphoserine Aminotransferase 1 and Activation of the mTOR/S6K Pathway.2025International journal of biological sciences
  4. GBP1-CDK9-STAT3 signaling axis promotes osteosarcoma PD-L1 expression and immune escape.2025Neoplasia (New York, N.Y.)
  5. KPNA2 promotes osteosarcoma progression by regulating the alternative splicing of DDX3X mediated by YBX1.2025Oncogene
  6. Signaling pathways and targeted therapies in Ewing sarcoma.2025Pharmacology & therapeutics
  7. Cyclin L1 participates in Adriamycin resistance and progression of osteosarcoma via PI3K/AKT-mTOR pathway.2024Aging
  8. Effects of Doxorubicin, Epirubicin, and Liposomal Doxorubicin (Anthracycline) on cardiac function in patients with osteosarcoma and their influencing factors.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  9. Single-cell RNA sequencing reveals SERPINE1-expressing CAFs remodelling tumour microenvironment in recurrent osteosarcoma.2024Clinical and translational medicine
  10. Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA.2024Drug development research
  11. Biomimetic bone-periosteum scaffold for spatiotemporal regulated innervated bone regeneration and therapy of osteosarcoma.2024Journal of nanobiotechnology
  12. Active targeting schemes for nano-drug delivery systems in osteosarcoma therapeutics.2023Journal of nanobiotechnology
  13. Network pharmacology-based research on the effect of Scutellaria baicalensis on osteosarcoma and the underlying mechanism.2023Medicine
  14. 2-Hydroxy-3-methylanthraquinone inhibits homologous recombination repair in osteosarcoma through the MYC-CHK1-RAD51 axis.2023Molecular medicine (Cambridge, Mass.)
  15. Targeted Delivery of PD-L1-Derived Phosphorylation-Mimicking Peptides by Engineered Biomimetic Nanovesicles to Enhance Osteosarcoma Treatment.2022Advanced healthcare materials
  16. Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.2022BMC cancer
  17. SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma.2022Cell death & disease
  18. LncCCAT1 interaction protein PKM2 upregulates SREBP2 phosphorylation to promote osteosarcoma tumorigenesis by enhancing the Warburg effect and lipogenesis.2022International journal of oncology
  19. Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy.2022Journal of controlled release : official journal of the Controlled Release Society
  20. Integrative analysis of immune-related multi-omics profiles identifies distinct prognosis and tumor microenvironment patterns in osteosarcoma.2022Molecular oncology
  21. Quercetin encapsulated in folic acid-modified liposomes is therapeutic against osteosarcoma by non-covalent binding to the JH2 domain of JAK2 Via the JAK2-STAT3-PDL1.2022Pharmacological research
  22. Single-cell transcriptomics reveals the regulative roles of cancer associated fibroblasts in tumor immune microenvironment of recurrent osteosarcoma.2022Theranostics
  23. CircRAB3IP upregulates twist family BHLH transcription factor (TWIST1) to promote osteosarcoma progression by sponging miR-580-3p.2021Bioengineered
  24. Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study.2021Journal of clinical pharmacy and therapeutics
  25. Amplification of oxidative stress with lycorine and gold-based nanocomposites for synergistic cascade cancer therapy.2021Journal of nanobiotechnology
Chinese-language papers (not in the count)1
  1. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].2022Zhonghua yi xue za zhi
Earlier papers (2016–2020)29
  1. Delivery of MutT homolog 1 inhibitor by functionalized graphene oxide nanoparticles for enhanced chemo-photodynamic therapy triggers cell death in osteosarcoma.2020Acta biomaterialia
  2. Key genes with prognostic values in suppression of osteosarcoma metastasis using comprehensive analysis.2020BMC cancer
  3. Surface engineering of nanoparticles with ligands for targeted delivery to osteosarcoma.2020Colloids and surfaces. B, Biointerfaces
  4. Hsa_circ_0000285 functions as a competitive endogenous RNA to promote osteosarcoma progression by sponging hsa-miRNA-599.2020Gene therapy
  5. PTBP1 modulates osteosarcoma chemoresistance to cisplatin by regulating the expression of the copper transporter SLC31A1.2020Journal of cellular and molecular medicine
  6. LncRNA CRNDE is activated by SP1 and promotes osteosarcoma proliferation, invasion, and epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway.2020Journal of cellular biochemistry
  7. Dysregulated circRNAs serve as prognostic and diagnostic markers in osteosarcoma by sponging microRNA to regulate the downstream signaling pathway.2020Journal of cellular biochemistry
  8. Dioscin inhibits the growth of human osteosarcoma by inducing G2/M-phase arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo.2020Journal of cellular physiology
  9. FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity.2020Theranostics
  10. MiR-19a as a prognostic indicator for cancer patients: a meta-analysis.2019Bioscience reports
  11. Association between TP53 rs1042522 gene polymorphism and the risk of malignant bone tumors: a meta-analysis.2019Bioscience reports
  12. Bruceine D inhibits tumor growth and stem cell-like traits of osteosarcoma through inhibition of STAT3 signaling pathway.2019Cancer medicine
  13. Transcriptional activation of CBFβ by CDK11p110 is necessary to promote osteosarcoma cell proliferation.2019Cell communication and signaling : CCS
  14. Dynasore suppresses cell proliferation, migration, and invasion and enhances the antitumor capacity of cisplatin via STAT3 pathway in osteosarcoma.2019Cell death & disease
  15. Integrative analyses of key genes and regulatory elements in fluoride-affected osteosarcoma.2019Journal of cellular biochemistry
  16. Prognostic value of prognostic nutritional index and systemic immune-inflammation index in patients with osteosarcoma.2019Journal of cellular physiology
  17. LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway.2019Journal of experimental & clinical cancer research : CR
  18. [Drug therapy of high grade osteosarcoma].2019Zhonghua yi xue za zhi
  19. The isolation, structural characterization and anti-osteosarcoma activity of a water soluble polysaccharide from Agrimonia pilosa.2018Carbohydrate polymers
  20. Reconstruction with constrained scapular prosthesis after total scapulectomy for scapular malignant tumor.2018Journal of surgical oncology
  21. RhoA/ROCK pathway inhibition by fasudil suppresses the vasculogenic mimicry of U2OS osteosarcoma cells in vitro.2017Anti-cancer drugs
  22. Triggering of apoptosis in osteosarcoma cells by graphene/single-walled carbon nanotube hybrids via the ROS-mediated mitochondrial pathway.2017Journal of biomedical materials research. Part A
  23. In vitro effect of microRNA-107 targeting Dkk-1 by regulation of Wnt/β-catenin signaling pathway in osteosarcoma.2017Medicine
  24. Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.2017Oncotarget
  25. Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11.2017Scientific reports
  26. p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines.2016Cancer chemotherapy and pharmacology
  27. Establishment and characterization of a novel osteosarcoma cell line: CHOS.2016Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  28. Clinical and biological significance of PIM1 kinase in osteosarcoma.2016Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  29. Long noncoding RNA MALAT1 as a potential therapeutic target in osteosarcoma.2016Journal of orthopaedic research : official publication of the Orthopaedic Research Society

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 18 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 3.4%.

Papers led
18
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 4420212022: 4420222023: 3320232024: 4420242025: 332025

9 hospitals in Wuhan for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

  2. Recruiting
    A Study of HQP1351 in Patients With GIST or Other Solid Tumors
    Phase
    Phase 1
    Started
    2018-07
    Registry
    NCT03594422

    Age 12 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologyPathology / laboratory medicine
Papers it led18
  1. Distinguishing very high-risk patients among high-risk gastrointestinal stromal tumor cases: development and validation of a nomogram based on a multicenter population-based retrospective cohort study.2025Annals of medicine
  2. Imatinib adherence prediction using machine learning approach in patients with gastrointestinal stromal tumor.2025Cancer
  3. Is lymph node metastasis an advanced event of gastrointestinal stromal tumor?2025The oncologist
  4. Development of a simultaneous quantification method of imatinib and sunitinib and their main metabolites and its application in patients with gastrointestinal stromal tumor.2024Biomedical chromatography : BMC
  5. Intratumoral microbiome promotes liver metastasis and dampens adjuvant imatinib treatment in gastrointestinal stromal tumor.2024Cancer letters
  6. Untargeted metabolomics analysis reveals the potential mechanism of imatinib-induced skin rash in patients with gastrointestinal stromal tumor.2024International immunopharmacology
  7. Ripretinib for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors.2024Journal of digestive diseases
  8. Targeting BCL6 in Gastrointestinal Stromal Tumor Promotes p53-Mediated Apoptosis to Enhance the Antitumor Activity of Imatinib.2023Cancer research
  9. Cardiovascular-Specific Mortality among Gastrointestinal Stromal Tumor Patients: A Population-Based Analysis.2023Oxidative medicine and cellular longevity
  10. Anaplastic lymphoma kinase expression in PDGFRA-mutated gastrointestinal stromal tumors probably correlates with poor prognosis.2023World journal of surgical oncology
  11. Clinicopathologic Characteristics and Prognosis of PDGFRA-Mutant Gastrointestinal Stromal Tumors: A Large-Scale, Multi-Institutional, Observational Study in China.2022Advances in therapy
  12. Laparoscopic Versus Open Surgery for Rectal Gastrointestinal Stromal Tumor: A Multicenter Propensity Score-Matched Analysis.2022Diseases of the colon and rectumRCT
  13. Association between preoperative skeletal muscle mass depletion and poor relapse-free survival in patients with gastrointestinal stromal tumors after complete resection.2022Nutrition (Burbank, Los Angeles County, Calif.)
  14. Safety and feasibility of laparoscopy-assisted surgery for gastrointestinal stromal tumors larger than 5 cm: Results of a retrospective, single-center series of 1,802 consecutive patients.2022Surgery
  15. Duodenal gastrointestinal stromal tumors: A retrospective study based on a 13 years experience of a single center in China.2021Asia-Pacific journal of clinical oncology
  16. Radical resection versus local excision for low rectal gastrointestinal stromal tumor: A multicenter propensity score-matched analysis.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  17. The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study.2021Journal of surgical oncology
  18. Efficacy of Endoscopic Ultrasound Elastography in Differential Diagnosis of Gastrointestinal Stromal Tumor Versus Gastrointestinal Leiomyoma.2021Medical science monitor : international medical journal of experimental and clinical research
Chinese-language papers (not in the count)4
  1. [Analysis of the efficacy of adjusting the dose of imatinib with therapeutic drug monitoring in adjuvant treatment after complete resection of gastrointestinal stromal tumors].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  2. [Clinicopathological characteristics and prognosis of patients with sporadic multiple primary gastrointestinal stromal tumors].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Pay attention to misdiagnosis and differential diagnosis of gastric gastrointestinal stromal tumor].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Earlier papers (2016–2020)17
  1. Elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis of patients with primary gastrointestinal stromal tumor.2020BMC gastroenterology
  2. ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report.2020Diagnostic pathology
  3. Development and validation of a prognostic nomogram to predict recurrence in high-risk gastrointestinal stromal tumour: A retrospective analysis of two independent cohorts.2020EBioMedicine
  4. Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.2020Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  5. Laparoscopic Versus Open Surgery for Gastric Gastrointestinal Stromal Tumors: a Propensity Score Matching Analysis.2020Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  6. Primary Gastrointestinal Stromal Tumor Mimicking as Gynecologic Mass: Characteristics, Management, and Prognosis.2020The Journal of surgical research
  7. [Characteristics and targeted therapy of wild-type gastrointestinal stromal tumor].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [A model to predict the recurrence of middle-high risk gastrointestinal stromal tumors based on preoperative fibrinogen and peripheral blood inflammatory indexes].2020Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. The prognostic value of gastrointestinal bleeding in gastrointestinal stromal tumor: A propensity score matching analysis.2019Cancer medicine
  10. Adherence to Adjuvant Imatinib Therapy in Patients with Gastrointestinal Stromal Tumor in Clinical Practice: A Cross-Sectional Study.2019Chemotherapy
  11. A Population-Based Study of the Incidence and Survival of Anorectal Gastrointestinal Stromal Tumor.2019Medical science monitor : international medical journal of experimental and clinical research
  12. [Laparoscopic versus open surgery for gastric gastrointestinal stromal tumors in unfavorable location: a propensity score-matching analysis].2019Zhonghua wai ke za zhi [Chinese journal of surgery]
  13. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].2019Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  14. Clinicopathological and Prognostic Analysis of Primary Gastrointestinal Stromal Tumor Presenting with Gastrointestinal Bleeding: a 10-Year Retrospective Study.2017Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  15. Clinicopathologic study of succinate-dehydrogenase-deficient gastrointestinal stromal tumors: A single-institutional experience in China.2017Medicine
  16. Clinicopathologic features and prognosis of primary gastrointestinal stromal tumor patients under 35 years of age: A 10-year retrospective study.2016Journal of surgical oncology
  17. [Clinical characteristics and prognosis analysis of 119 cases with giant gastrointestinal stromal tumor].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status5
  1. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05
  2. A Study of HQP1351 in Patients With GIST or Other Solid TumorsRecruitingNCT03594422Study sitePhase 1Start 2018-07
  3. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibCompletedNCT04633122Study sitePhase 2Start 2020-11
  4. A Study of CS3007 in Subjects With Gastrointestinal Stromal TumorCompletedNCT04254939Study sitePhase 1/Phase 2Start 2019-08
  5. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GISTCompletedNCT03465722Study sitePhase 3Start 2018-03

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 8 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
8
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 3320232024: 2220242025: 112025

11 hospitals in Wuhan for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsNeurology

Over half of these papers are lab or animal studies.

Papers it led8
  1. Targeting RBM10-Repressed RORB Activity in Liquid Condensates Inhibits Lysosomal Biogenesis and Neuroblastoma Progression via Affecting NF-κB Signaling.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  2. Targeting c-Myc transactivation by LMNA inhibits tRNA processing essential for malate-aspartate shuttle and tumour progression.2024Clinical and translational medicine
  3. YY1 drives PARP1 expression essential for PARylation of NONO in mRNA maturation during neuroblastoma progression.2024Journal of translational medicine
  4. Therapeutic targeting of CNBP phase separation inhibits ribosome biogenesis and neuroblastoma progression via modulating SWI/SNF complex activity.2023Clinical and translational medicine
  5. SIRT3 ameliorates diabetes-associated cognitive dysfunction via regulating mitochondria-associated ER membranes.2023Journal of translational medicine
  6. Therapeutic targeting of FUBP3 phase separation by GATA2-AS1 inhibits malate-aspartate shuttle and neuroblastoma progression via modulating SUZ12 activity.2023Oncogene
  7. HNF4A-AS1-encoded small peptide promotes self-renewal and aggressiveness of neuroblastoma stem cells via eEF1A1-repressed SMAD4 transactivation.2022Oncogene
  8. Lead exposure represses mitochondrial metabolism by activation of heme-binding protein BACH1 in differentiated SH-SY5Y cell.2022The Science of the total environment
Earlier papers (2016–2020)13
  1. Long Noncoding RNA NHEG1 Drives β-Catenin Transactivation and Neuroblastoma Progression through Interacting with DDX5.2020Molecular therapy : the journal of the American Society of Gene Therapy
  2. Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression.2020Theranostics
  3. SNW1 regulates Notch signaling in neuroblastoma through interacting with RBPJ.2019Biochemical and biophysical research communications
  4. Valproic acid suppresses Warburg effect and tumor progression in neuroblastoma.2019Biochemical and biophysical research communications
  5. Therapeutic targeting of circ-CUX1/EWSR1/MAZ axis inhibits glycolysis and neuroblastoma progression.2019EMBO molecular medicine
  6. Long Noncoding RNA pancEts-1 Promotes Neuroblastoma Progression through hnRNPK-Mediated β-Catenin Stabilization.2018Cancer research
  7. DAPK1-ERK signal mediates oxygen glucose deprivation reperfusion induced apoptosis in mouse N2a cells.2018Journal of the neurological sciences
  8. Armadillo repeat containing 12 promotes neuroblastoma progression through interaction with retinoblastoma binding protein 4.2018Nature communications
  9. Overexpression of Tau Rescues Nogo-66-Induced Neurite Outgrowth Inhibition In Vitro.2016Neuroscience bulletin
  10. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.2016Oncogene
  11. microRNA-558 facilitates the expression of hypoxia-inducible factor 2 alpha through binding to 5'-untranslated region in neuroblastoma.2016Oncotarget
  12. Smad4 suppresses the tumorigenesis and aggressiveness of neuroblastoma through repressing the expression of heparanase.2016Scientific reports
  13. Risk stratification and therapeutics of neuroblastoma: the challenges remain.2016World journal of pediatrics : WJP
All its trials on ClinicalTrials.gov, any status1
  1. Diagnostic Efficacy and Prognostic Value of 18F-FDG PET/CT (MR) in Pediatric Solid BlastomaCompletedNCT06190574Lead sponsorStart 2021-07

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

6 hospitals in Wuhan for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 30 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.8%.

Papers led
30
2021–2025
Trials led
10
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 4420212022: 3320222023: 7720232024: 9920242025: 662025

3 hospitals in Wuhan for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 11

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
    Phase
    Early phase 1
    Started
    2026-03
    Registry
    NCT07429721

    Age 18 years to Not stated (registered criteria)

    Led by Union HospitalWuhan

  2. Recruiting
    An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
    Phase
    Early phase 1
    Started
    2025-09
    Registry
    NCT07101705

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  3. Recruiting
    The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical Trial
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06228794

    Age 18 years to 80 years (registered criteria)

    Led by Union HospitalWuhan

  4. Recruiting
    Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
    Phase
    Phase 2
    Started
    2023-10
    Registry
    NCT06140966

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

  5. Not yet recruiting
    Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma
    Phase
    Phase 3
    Started
    2025-09
    Registry
    NCT06580223

    Age 18 years to 90 years (registered criteria)

    Led by Union HospitalWuhan

  6. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  7. Recruiting
    LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2025-09
    Registry
    NCT07100067

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Wuhan

  8. Recruiting
    A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
    Phase
    Phase 3
    Started
    2024-06
    Registry
    NCT06508983

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Wuhan, Xi'an, Zhengzhou

  9. Recruiting
    A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06049290

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Guiyang, Haikou, Hangzhou, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  10. Recruiting
    OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06182696

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Nanjing, Shanghai, Wuhan

  11. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskCAR-T & cell therapyBispecific & antibody drugs
Departments in papersRadiology / nuclear medicine
Papers it led30
  1. Global burden of multiple myeloma in older adults from 1990 to 2021 and modeled projection to 2050.2026International journal of surgery (London, England)
  2. Targeted Delivery of c(RGDfk)-Modified Liposomes to Bone Marrow Through In Vivo Hitchhiking Neutrophils for Multiple Myeloma Therapy.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis.2025Annals of medicineFree full text
  4. Integrating single-cell and bulk RNA profiles to uncover glutamine metabolism's role in prognosis and immune dynamics in multiple myeloma.2025BMC cancerFree full text
  5. Macrophage migration inhibitory factor as a prognostic biomarker in multiple myeloma: clinical significance and in vitro effects.2025Carcinogenesis
  6. ZNF655 involved in the progression of multiple myeloma via the activation of AKT.2025Cell biology international
  7. Polymerase theta inhibition impairs tumor growth and amplifies melphalan-induced DNA damage in multiple myeloma.2025Journal of translational medicineFree full text
  8. ALKHB5-demethylated lncRNA SNHG15 promotes myeloma tumorigenicity by increasing chromatin accessibility and recruiting H3K36me3 modifier SETD2.2024American journal of physiology. Cell physiologyFree full text
  9. Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis.2024Annals of medicineFree full text
  10. Class II ferroptosis inducers are a novel therapeutic approach for t(4;14)-positive multiple myeloma.2024Blood advancesFree full text
  11. Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy.2024Frontiers in bioscience (Landmark edition)
  12. Different evasion strategies in multiple myeloma.2024Frontiers in immunologyFree full text
  13. GLYR1 transcriptionally regulates PER3 expression to promote the proliferation and migration of multiple myeloma.2024Genomics
  14. Development of a nomogram prognostic model for early Grade ≥ 3 infection in newly diagnosed multiple myeloma based on immunoparesis.2024International immunopharmacology
  15. Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma.2024LeukemiaFree full text
  16. Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?2024The Lancet. Haematology
  17. Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.2023Annals of medicineFree full text
  18. Multiple immunoglobulin isotype switch after bispecific CAR-T cell therapy in multiple myeloma-A case report.2023British journal of haematology
  19. MALAT1 regulates network of microRNA-15a/16-VEGFA to promote tumorigenesis and angiogenesis in multiple myeloma.2023Carcinogenesis
  20. ACSL4: a double-edged sword target in multiple myeloma, promotes cell proliferation and sensitizes cell to ferroptosis.2023Carcinogenesis
  21. CCL18 promotes migration and invasion of multiple myeloma cells and is associated with poor prognosis.2023Carcinogenesis
  22. A prognostication system based on clinical parameters and [18F]-FDG PET/CT in patients with newly diagnosed multiple myeloma.2023European journal of nuclear medicine and molecular imaging
  23. The risk factors for coagulation disorder of chimeric antigen receptor-T cell therapy in patients with hematological tumors: A systematic review and meta-analysis.2023Technology and health care : official journal of the European Society for Engineering and Medicine
  24. Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma.2022Frontiers in immunologyFree full text
  25. ALKBH5 Promotes Multiple Myeloma Tumorigenicity through inducing m6A-demethylation of SAV1 mRNA and Myeloma Stem Cell Phenotype.2022International journal of biological sciencesFree full text
  26. FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner.2022Molecular therapy : the journal of the American Society of Gene TherapyFree full text
  27. Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma.2021International immunopharmacology
  28. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.2021Journal of hematology & oncologyFree full text
  29. JunB is a key regulator of multiple myeloma bone marrow angiogenesis.2021LeukemiaFree full text
  30. COVID-19 in patients with multiple myeloma: a cross-sectional survey from the most severely affected region in China.2021Leukemia & lymphoma
Chinese-language papers (not in the count)5
  1. [Development, reliability, and validity of a treatment-related quality of life scale for Chinese patients with multiple myeloma].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [BCMA/CS1 bispecific CAR-T cell therapy for multiple myeloma complicated with thrombocytopenia: a case report and literature review].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  3. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  4. [Update on biology of primary plasma cell leukemia].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  5. [Clinical characteristics of patients with multiple myeloma harboring 6q deletion].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status29
  1. A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.RecruitingNCT07429721Lead sponsorEarly phase 1Start 2026-03
  2. Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple MyelomaNot yet recruitingNCT06580223Lead sponsorPhase 3Start 2025-09
  3. An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological MalignanciesRecruitingNCT07101705Lead sponsorEarly phase 1Start 2025-09
  4. The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical TrialRecruitingNCT06228794Lead sponsorStart 2024-04
  5. Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaRecruitingNCT06140966Lead sponsorPhase 2Start 2023-10
  6. Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMMStatus unknownNCT06503107Lead sponsorPhase 1/Phase 2Start 2024-04
  7. A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.SuspendedNCT06691685Lead sponsorEarly phase 1Start 2024-11
  8. A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of TherapyStatus unknownNCT05998928Lead sponsorPhase 2Start 2023-07
  9. Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic MalignanciesStatus unknownNCT05672420Lead sponsorPhase 1/Phase 2Start 2023-01
  10. T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple MyelomaStatus unknownNCT04662099Lead sponsorPhase 1Start 2020-03
  11. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  12. LCAR-F33S in Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT07100067Study siteN/AStart 2025-09
  13. A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma PatientsRecruitingNCT06508983Study sitePhase 3Start 2024-06
  14. A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Study sitePhase 1/Phase 2Start 2023-10
  15. OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMMRecruitingNCT06182696Study sitePhase 1/Phase 2Start 2023-10
  16. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  17. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06158841Study sitePhase 3Start 2024-05
  18. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  19. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05572515Study sitePhase 3Start 2023-03
  20. A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple MyelomaTerminatedNCT05590377Study sitePhase 1/Phase 2Start 2023-01
  21. ATG-010(Selinexor) in Combination With Chemotherapy in RRMMStatus unknownNCT04877275Study sitePhase 2Start 2021-05
  22. Evaluate CART-BCMA in Patients With Relapsed and/or Refractory Multiple MyelomaStatus unknownNCT05346198Study sitePhase 1Start 2021-03
  23. APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple MyelomaStatus unknownNCT04674514Study sitePhase 1/Phase 2Start 2021-04
  24. Dual-target CAR-T Cells (C-4-29) in the Treatment of Relapsed/Refractory Multiple MyelomaStatus unknownNCT04861480Study sitePhase 1Start 2021-06
  25. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  26. A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Study sitePhase 3Start 2018-10
  27. A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple MyelomaTerminatedNCT03215030Study sitePhase 1/Phase 2Start 2017-10
  28. Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer IndicationsCompletedNCT02649790Study sitePhase 1/Phase 2Start 2016-01
  29. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)TerminatedNCT01947309Study siteStart 2013-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 3 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 1.3%.

Papers led
3
2021–2025
Trials led
7
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025

3 hospitals in Wuhan for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults
    Phase
    Early phase 1
    Started
    2026-04
    Registry
    NCT07470073

    Age 12 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  2. Recruiting
    CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Registry
    NCT06735495

    Age 3 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

  3. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  4. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  5. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

  6. Recruiting
    The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic Leukemia
    Phase
    Early phase 1
    Started
    2024-03
    Registry
    NCT06307600

    Age 3 years to 70 years (registered criteria)

    Led by First Affiliated Hospital of USTC; 1 listed hospital as study siteHefei, Wuhan

  7. Recruiting
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06450067

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  8. Recruiting
    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Registry
    NCT05667506

    Age 3 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChongqing, Guangzhou, Hefei, Nanchang, Nanjing, Tianjin, Wuhan, Xuzhou

  9. Recruiting
    A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
    Phase
    Phase 1/Phase 2
    Started
    2022-11
    Registry
    NCT05579132

    Age 2 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesChengdu, Chongqing, Guangzhou, Hangzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesCAR-T & cell therapyChildrenSide effects (CRS, neurotoxicity)
Departments in papersMedical oncology
Papers it led3
  1. Novel Prognostic Scoring Systems for Severe CRS after Anti-CD19 CAR-T-Cells in Acute B-Lymphoblastic Leukemia.2025Current medical scienceFree full text
  2. Biomarkers for predicting CAR-T cell therapy outcomes in B-cell acute lymphoblastic leukemia: a systematic review.2025Frontiers in immunologyFree full text
  3. Bone marrow blasts- and modified EASIX-guided risk stratification for coagulopathy and outcomes after CAR-T therapy in relapsed/refractory B-ALL.2025Thrombosis research
Chinese-language papers (not in the count)2
  1. [The mechanisms and salvage treatment strategies underlying positive relapse following CD19 CAR-T cell therapy in B-acute lymphoblastic leukemia].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status19
  1. A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and AdultsRecruitingNCT07470073Lead sponsorEarly phase 1Start 2026-04
  2. CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic TumorsRecruitingNCT06735495Lead sponsorPhase 1/Phase 2Start 2024-11
  3. CD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological TumorsStatus unknownNCT06503094Lead sponsorPhase 1/Phase 2Start 2024-01
  4. Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T TherapiesActive, not recruitingNCT06220097Lead sponsorPhase 2Start 2022-02
  5. Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid MalignanciesStatus unknownNCT04796675Lead sponsorPhase 1Start 2021-04
  6. Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological MalignanciesStatus unknownNCT04796688Lead sponsorPhase 1Start 2021-03
  7. Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy for Relapsed Refractory B-cell MalignanciesStatus unknownNCT04007978Lead sponsorPhase 1Start 2019-08
  8. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL ProtocolRecruitingNCT06764238Study sitePhase 2/Phase 3Start 2025-01
  9. Newly-diagnosed Pediatric Ph-positive B-ALL ProtocolRecruitingNCT07152041Study sitePhase 3Start 2025-03
  10. Newly-diagnosed Low Risk Pediatric B-cell ALL ProtocolRecruitingNCT06882057Study sitePhase 2/Phase 3Start 2025-03
  11. Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic LeukemiaRecruitingNCT06450067Study siteStart 2024-06
  12. The Safety and Efficacy of RD06-03 CART Cell Injection in Patients With R/R Acute B-lymphoblastic LeukemiaRecruitingNCT06307600Study siteEarly phase 1Start 2024-03
  13. A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)RecruitingNCT05667506Study sitePhase 1/Phase 2Start 2023-02
  14. A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)RecruitingNCT05579132Study sitePhase 1/Phase 2Start 2022-11
  15. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Study sitePhase 1/Phase 2Start 2021-01
  16. Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell MalignanciesStatus unknownNCT04008251Study sitePhase 1Start 2019-05
  17. Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell MalignanciesStatus unknownNCT03366350Study sitePhase 1/Phase 2Start 2016-04
  18. Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell MalignanciesStatus unknownNCT03366324Study sitePhase 1/Phase 2Start 2016-05
  19. CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell MalignanciesStatus unknownNCT02965092Study sitePhase 1/Phase 2Start 2015-12

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 2 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

4 hospitals in Wuhan for aplastic anaemia63 hospitals in China for aplastic anaemia

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07552506

    Age 14 years to 50 years; women only (registered criteria)

    Led by Union Hospital; 3 listed hospitals as study sitesHangzhou, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImmunosuppressive treatmentChildren
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 8 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 2.0%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 3320242025: 332025

2 hospitals in Wuhan for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07208058

    Age 16 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEBV & infection triggersTreatment regimensLymphoma & cancer-related HLH
Departments in papersPediatricsMedical oncology
Papers it led8
  1. Development and validation of a predictive model for diagnosing EBER-positive lymphoma-associated hemophagocytic lymphohistiocytosis.2025BMC cancerFree full text
  2. C3 as a predictive and prognostic biomarker in adult hemophagocytic lymphohistiocytosis: a large cohort study in China.2025Blood advancesFree full text
  3. Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies.2025Expert review of clinical immunology
  4. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.2024International journal of pharmaceutics
  5. Clinical utility of plasma Epstein-Barr virus DNA monitoring in pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: a Chinese retrospective observational study.2024Italian journal of pediatricsFree full text
  6. Clinical significance and different strategies for re-elevation of plasma EBV-DNA during treatment in pediatric EBV-associated hemophagocytic lymphohistiocytosis.2024Jornal de pediatriaFree full text
  7. Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis complicated by neurological involvement in a patient with dermatomyositis: A case report and literature review.2023Modern rheumatology case reports
  8. Hemophagocytic lymphohistiocytosis after COVID-19 vaccination.2021Journal of hematology & oncologyFree full text
Chinese-language papers (not in the count)1
  1. [Clinical Characteristics and Prognosis of Children with Hematological Malignancies Complicated by Secondary Hemophagocytic Lymphohistiocytosis].2025Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status1
  1. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])RecruitingNCT07208058Study sitePhase 3Start 2025-11
More papers found outside PubMed (not counted)3
  1. CLAMP: A phase II prospective study of camrelizumab combined with pegaspargase, etoposide, and high-dose methotrexate in patients with natural killer (NK)/T-cell lymphoma.2024Journal of Clinical Oncologyconference-abstract
  2. Clinical features and prognostic factors of adult patients with hemophagocytic lymphohistiocytosis: a retrospective study of 130 adult patients2022Research Squarepreprint
  3. Pattern and Prognosis of Distant Metastases in Patients with Early-Stage Extranodal Nasal-Type NK/T-Cell Lymphoma2022International Journal of Radiation Oncology*Biology*Physicsarticle

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Wuhan for haemophilia A160 hospitals in China for haemophilia A

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06833983

    Age 18 years to 65 years; men only (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Tangshan, Tianjin, Wuhan, Zhengzhou

  2. Recruiting
    Evaluation of the Safety and Efficacy of Hemophilia A Gene Therapy Drugs
    Phase
    Phase 2/Phase 3
    Started
    2024-01
    Registry
    NCT06111638

    Age 18 years to Not stated; men only (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Guiyang, Kunming, Suzhou, Tianjin, Wuhan, Xi’an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Wuhan for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 1 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Wuhan for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosis

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led no English-language PubMed papers on IgG4-related disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Wuhan for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune DiseasesWithdrawnNCT07583030Lead sponsorEarly phase 1Start 2026-09
More papers found outside PubMed (not counted)1
  1. Potential roles of antibodies with different classes in IgG4‐related diseases2025Rheumatology & autoimmunityarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led no English-language PubMed papers on myasthenia gravis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Wuhan for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07470151

    Age 18 years to 70 years (registered criteria)

    Led by Union HospitalWuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status4
  1. Clinical Study of EVM18001 in the Treatment of Refractory Autoimmune DiseasesRecruitingNCT07470151Lead sponsorN/AStart 2026-03
  2. A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune DiseasesWithdrawnNCT07583030Lead sponsorEarly phase 1Start 2026-09
  3. A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune DiseasesWithdrawnNCT06869278Lead sponsorPhase 1Start 2025-06
  4. Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Study sitePhase 3Start 2023-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

3 hospitals in Wuhan for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesGenetics
Departments in papersNeurosurgery
Papers it led2
  1. Progress in the application of stem cell therapy for moyamoya disease.2025Biochemical and biophysical research communications
  2. Identification of the potential role of S1PR1 in adult moyamoya disease based on multiple bioinformatics analysis and experimental verification.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
More papers found outside PubMed (not counted)1
  1. Mycoplasma pneumoniae-associated cerebral infarction in a child: A case report and literature review2025Medicine Case Reports and Study Protocolsarticle

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led 7 of the 214 English-language PubMed papers on biliary atresia with an author in mainland China, 2021–2025: 3.3%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 442025

2 hospitals in Wuhan for biliary atresia28 hospitals in China for biliary atresia

No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesKasai operationLong-term outcomesScreening & diagnosis
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 2 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

5 hospitals in Wuhan for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led2
  1. Decoding NMDAR encephalitis: proteomic markers and computational identification of potential therapeutic pathways.2025Brain, behavior, and immunity
  2. Intrathecal treatment of Anti-N-Methyl-D-Aspartate receptor encephalitis: a promising approach for refractory cases.2025Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 1 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Wuhan for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. Multiple Aneurysms of the Subclavian-Axillary, Abdominal Aortoiliac, Lower Extremity, and Coronary Arteries in A Pediatric Patient of Takayasu Arteritis.2022Annals of vascular surgery
Earlier papers (2016–2020)1
  1. Involvement of the Bicuspid Aortic Valve Mimicking a Mass in Takayasu Arteritis.2018Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
All its trials on ClinicalTrials.gov, any status1
  1. Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's ArteritisNot yet recruitingNCT07451665Study sitePhase 4Start 2026-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 3 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.3%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

9 hospitals in Wuhan for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led3
  1. Pre-exposure to Aerosolized Polyvalent Bacterial Lysates Protects Against Bleomycin-Induced Pulmonary Fibrosis in Mice.2022Inflammation
  2. Pleural mesothelial cell migration into lung parenchyma by calpain contributes to idiopathic pulmonary fibrosis.2022Journal of cellular physiology
  3. VEGF/Src signaling mediated pleural barrier damage and increased permeability contributes to subpleural pulmonary fibrosis.2021American journal of physiology. Lung cellular and molecular physiology
Earlier papers (2016–2020)3
  1. Cigarette smoking aggravates bleomycin-induced experimental pulmonary fibrosis.2019Toxicology letters
  2. Emodin Attenuates Bleomycin-Induced Pulmonary Fibrosis via Anti-Inflammatory and Anti-Oxidative Activities in Rats.2018Medical science monitor : international medical journal of experimental and clinical research
  3. miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-β Receptor II.2017Molecular therapy : the journal of the American Society of Gene Therapy
All its trials on ClinicalTrials.gov, any status6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary FibrosisNot yet recruitingNCT07131150Study sitePhase 2Start 2025-08
  3. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  4. A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05321069Study sitePhase 3Start 2022-10
  5. Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT04419558Study sitePhase 3Start 2020-09
  6. Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)TerminatedNCT03955146Study sitePhase 3Start 2019-06

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Wuhan for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Exploring the genetics and non-cell autonomous mechanisms underlying ALS/FTLD.2018Cell death and differentiation

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Wuhan for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

8 hospitals in Wuhan for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of YKST02 in Participants With Primary IgA Nephropathy
    Phase
    Early phase 1
    Started
    2026-05
    Registry
    NCT07498673

    Age 18 years to 75 years (registered criteria)

    Led by Union HospitalWuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology
Papers it led2
  1. Causal association between peripheral immune cells and IgA nephropathy: a Mendelian randomization study.2024Frontiers in immunology
  2. Research advances on targeted-Treg therapies on immune-mediated kidney diseases.2023Autoimmunity reviews
All its trials on ClinicalTrials.gov, any status4
  1. A Study of YKST02 in Participants With Primary IgA NephropathyRecruitingNCT07498673Lead sponsorEarly phase 1Start 2026-05
  2. Model Development and Application Based on Renal Pathology ImagesActive, not recruitingNCT07816874Lead sponsorStart 2019-01
  3. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Wuhan for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 3 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 112025

5 hospitals in Wuhan for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led no English-language PubMed papers on primary sclerosing cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Wuhan for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led 1 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Wuhan for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led1
  1. Multimodality Imaging of Congenital Intrapericardial Diaphragmatic Hernia.2024Radiology. Cardiothoracic imaging

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 8 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 5.0%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 332025

3 hospitals in Wuhan for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led8
  1. Tight junction dysfunction and cytoskeletal remodeling in Hirschsprung‑associated enterocolitis: A decade of mechanistic insights and therapeutic prospects (Review).2026Molecular medicine reports
  2. Robotic-assisted Proctosigmoidectomy Versus Laparoscopic-assisted Soave Pull-through for Hirschsprung Disease: Medium-term Outcomes From a Prospective Multicenter Study.2025Annals of surgery
  3. Whole-genome sequencing identified ALK as a novel susceptible gene of Hirschsprung disease.2025Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology
  4. Secretagogin Downregulation Impairs Nerve Cell Migration in Hirschsprung Disease via Inhibition of the LEF-1/NCAM1 Axis.2025Molecular & cellular proteomics : MCP
  5. Update on the Pathogenesis of the Hirschsprung-Associated Enterocolitis.2023International journal of molecular sciences
  6. Robotic-assisted proctosigmoidectomy for Hirschsprung's disease: A multicenter prospective study.2023World journal of gastroenterology
  7. Hirschsprung's disease: key microRNAs and target genes.2022Pediatric research
  8. Skip segment Hirschsprung's disease: diagnostic clues and surgical management.2021Pediatric surgery international
Earlier papers (2016–2020)12
  1. Resuturing Without Enterostomy for the Treatment of Early-Stage Anastomotic Leaks After Laparoscopic Soave Procedure in Hirschsprung's Disease.2020Journal of laparoendoscopic & advanced surgical techniques. Part A
  2. Primary laparoscopic endorectal pull-through procedure with or without a postoperative rectal tube for hirschsprung disease: a multicenter perspective study.2020Journal of pediatric surgeryRCT
  3. Laparoscopic Redo Pull-Through for Hirschsprung Disease Due to Innervation Disorders.2019Journal of laparoendoscopic & advanced surgical techniques. Part A
  4. Increased miR-214 expression suppresses cell migration and proliferation in Hirschsprung disease by interacting with PLAGL2.2019Pediatric research
  5. Transumbilical enterostomy for Hirschsprung's disease with a two-stage laparoscopy-assisted pull-through procedure.2019World journal of gastroenterology
  6. Duhamel operation vs. transanal endorectal pull-through procedure for Hirschsprung disease: A systematic review and meta-analysis.2018Journal of pediatric surgery
  7. Laparoscopic-assisted Duhamel procedure with ex-anal rectal transection for total colonic aganglionosis.2018Journal of pediatric surgery
  8. Gli family zinc finger 1 is associated with endothelin receptor type B in Hirschsprung disease.2018Molecular medicine reports
  9. Laparoscopic Duhamel Procedure with Ex-Anal Rectal Transection for Right-Sided Hirschsprung's Disease.2017Journal of laparoendoscopic & advanced surgical techniques. Part A
  10. Neuregulin 1 is involved in enteric nervous system development in zebrafish.2017Journal of pediatric surgery
  11. Effects of NRG1 Polymorphisms on Hirschsprung's Disease Susceptibility: A Meta-analysis.2017Scientific reports
  12. Effects of RET, NRG1 and NRG3 Polymorphisms in a Chinese Population with Hirschsprung Disease.2017Scientific reports

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Wuhan for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

华中科技大学同济医学院附属协和医院

Union Hospital

武汉

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Wuhan Union Hospital; Union Hospital of Tongji Medical College; Huazhong University of Science and Technology; Union Hospital Tongji Medical College; Union Hospital Wuhan; Union Hospital of Huazhong University of Science and Technology; Union Hospital Affiliated to Tongji Medical College; Tongji Medical College Union Hospital

Suggest a correctionDownload the data